Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin ( VIM ), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and multinucleation in transformed VIM-expressing mesenchymal cancer cells. Vimentin-IN-1 shows better oral bioavailability and pharmacokinetic profiles than FiVe1 In Vitro Vimentin-IN-1 (compound 4e) (0-10 mM; 72 h) inhibits a marked improvement in potency with an IC 50 value of 44 nM against HT-1080 fibrosarcoma, better than than FiVe1 (IC 50 =1.6 μM, HT-1080). Vimentin-IN-1 (0.1 μM; 24 h) induces phosphorylation of VIM at Ser56. Vimentin-IN-1 (100 μM; sampled at 0, 5, 15, 30, 45, and 60 min) exhibits poor stability with 0.0% remaining after 60 min of incubation in mouse liver microsome. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HT-1080, RD, and MCF-7 cells Concentration: 0-10 mM Incubation Time: 72 hours Result: Inhibited HT-1080, RD, and MCF-7 cells with IC 50 s of 44 nM, 61 nM, and 49 nM, respectively. In Vivo Vimentin-IN-1 (compound 4e) (10 mg/kg; p.o.; single dose) shows better oral pharmacokinetic properties than Five1 . Pharmacokinetic properties of Vimentin-IN-1 in mice Route Dose (mg/kg) AUC 0-last (ng·h/mL) AUC 0-inf (ng·h/mL) T 1/2 (h) T max (h) T last (h) C max (ng/mL) 4e PO 10 371.33 534.33 4.68 0.67 8 154.67 4e IP 1 208.33 211.33 0.59 0.25 4 197.00 Five1 PO 25 309.78 339.21 4.57 0.5 18 110.43 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:vimentin (VIM)